Dublin, Dec. 14, 2017 -- The "Haemophilia Forecast in 17 Major Markets 2017-2027" report has been added to Research and Markets' offering.
This report covers the two main types of the disease, haemophilia A (factor VIII deficiency) and B (factor IX deficiency), both of which are X-linked recessive disorders that are much more common in males, as well as acquired haemophilia, a very rare autoimmune disorder caused by abnormal immune system autoreactivity, resulting in clotting factor deficiency (usually factor VIII) and signs and symptoms similar to those of HA/HB.
This report provides the current prevalent population for haemophilia across 17 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Greece, Turkey, Russia, Japan, China, India, Australia, Brazil, Mexico) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight, sub-populations with the covered types of haemophilia, as well as several of the main symptoms and co-morbidities of haemophilia and clinical features thereof have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for haemophilia include:
- Development of inhibitors
- Haemophilic arthropathy
- Reduced bone density
- Cirrhosis
- Hepatocellular carcinoma
Key Topics Covered:
- Introduction
- Cause of the Disease
- Risk Factors & Prevention
- Diagnosis of the Disease
- Variation by Geography/Ethnicity
- Disease Prognosis & Clinical Course
- Key Comorbid Conditions / Features Associated With the Disease
- Methodology for Quantification of Patient Numbers
- Top-Line Prevalence for Haemophilia
- Features of Haemophilia Patients
- Haemophilia a Patients
- Haemophilia B Patients
- Acquired Haemophilia Patients
- Comorbid Conditions of Haemophilia Patients
- Haemophilic Arthropathy
- Other Comorbid Conditions
- Abbreviations Used in the Report
- Other Publications
- Online Patient-Based Databases
- Patient-Based Offering
- Online Pricing Data & Platforms
- References
- Appendix
For more information about this report visit https://www.researchandmarkets.com/research/w9gj96/haemophilia?w=12
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Hematology


Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Instagram Outage Disrupts Thousands of U.S. Users
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 



